Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pilot study of AmBisome primary antifungal prophylaxis after allogeneic stem-cell transplantation
2004-003745-40Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amphotericin b in invasive mycoses and mycoses, sponsored by Gilead Sciences. Primary endpoints: Infusion-related adverse events and Nephrotoxicity. Started Jun 2005; status: completed.
02
Drugs
amphotericin b
03
Conditions
invasive mycosesmycoses
Beyond the preview
Go deeper on 2004-003745-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003745-40.